[Federal Register Volume 64, Number 99 (Monday, May 24, 1999)]
[Notices]
[Pages 27994-27999]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-12996]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Program Announcement 99102]
Interventional Epidemiologic Research Studies of HIV/AIDS Among
Pregnant Women, Children, and Adolescents; Availability of Funds
A. Purpose
The Centers for Disease Control and Prevention (CDC) announces the
availability of fiscal year (FY) 1999 funds for a cooperative agreement
program for new and competitive continuation cooperative agreements for
interventional epidemiologic research studies of HIV/AIDS among
pregnant women, children, and adolescents. This program addresses the
``Healthy People 2000'' priority areas of HIV Infection and Maternal
and Infant Health. The purpose of the program is to support researchers
in the conduct of HIV interventional epidemiologic research studies
that foster prevention of HIV infection or HIV-related disease in
infants, children, and adolescents. These include studies that address:
(I) Mother infant rapid intervention at delivery (MIRIAD), (II) follow-
up of perinatally HIV-infected children, and (III) parent communication
training interventions with longitudinal follow-up among populations of
color at high risk for infection for sexually transmitted diseases
(STD) including HIV.
Research Studies
(I) Mother Infant Rapid Intervention at Delivery (MIRIAD)
Most HIV-infected pregnant women in the United States use hospitals
for delivery, providing a crucial opportunity for systematic screening
and intervention when indicated. In
[[Page 27995]]
some parts of the country, more infants might be spared HIV infection
if the benefits of intrapartum/neonatal zidovudine (ZDV) were extended
to pregnant women with little or no prenatal care than if transmission
rates were further reduced among cohorts already receiving standard
ACTG-076 therapy.
The MIRIAD Project should assess (1) a 24-hour counseling and
voluntary rapid HIV testing program among women in labor presenting
with unknown HIV status; (2) the feasibility of obtaining informed
consent during labor (or, if not feasible, soon after birth); (3)
reasons for lack of prenatal care among these women; (4) the rapid
implementation and assessment of antiretroviral therapy--mono therapy
or more intensive regimens--given at labor and delivery or to the
neonate; (5) adherence to neonatal therapy; and (6) subsequent receipt
of antiretroviral treatment and other services for women identified as
HIV infected.
Innovative implementation strategies for the prevention of
perinatal HIV transmission in settings where many HIV-infected women
continue to receive little or no prenatal care are encouraged. Novel
approaches for rapid bedside testing of women in labor and post-test
counseling and referral/connection to care for HIV positive women and
their infants should be carefully piloted at each site during the first
12-18 months of the funding period. A sustainable full-time in-labor
(or, if not feasible, postpartum) counseling, testing and ZDV
chemoprophylaxis intervention program should be instituted according to
the standard of care at each participating site no later than 18 months
into the funding period. Late-registrant mothers presenting after 36
weeks of pregnancy with unknown HIV status should also be offered rapid
HIV testing and antiretroviral therapy during late pregnancy,
intrapartum and to the neonate.
Administration of intravenous ZDV intrapartum (if possible) and
oral ZDV to the neonate as soon as possible and within 48 hours of
birth should be recommended as the minimum standard of perinatal HIV
preventive care for HIV-infected women presenting in labor. More
intensive antiretroviral therapy such as combination therapy should be
presented as an option with possible post exposure prophylaxis benefit
over mono therapy. Perinatal HIV transmission risk associated with
various components of the antiretroviral intervention (e.g., neonatal
only administration versus intrapartum + neonatal) will be compared
while attempting to control for possible confounders. Results from
these studies should facilitate recommendations and provide
effectiveness and operational research data on rapid HIV testing and
administration of antiretrovirals among late-registrant women
presenting in delivery rooms with unknown HIV status.
At each Project site, it is expected that a minimum of 1000 women
will receive rapid HIV testing and counseling per year; and that a
minimum of 20 HIV positive mother-infant pairs will be identified
(after 36 weeks of pregnancy, during labor or within 48 hours after
birth) and enrolled in MIRIAD annually. In order to reach these numbers
and serve a large, population-based sample of disadvantaged women with
high HIV sero prevalence and inadequate prenatal care, primary project
sites are encouraged to collaborate with 2-3 other hospitals or
maternity clinics within their geographic area. In the second and third
year of the project, based on experience gained from the MIRIAD
project, funded sites will be asked to develop outreach programs to
assist other hospitals in their area implement rapid counseling and HIV
testing at labor, and delivery of peripartum antiretroviral
interventions.
Rapid testing for HIV during the peripartum period has the
potential to improve clinical outcomes for both women and their infants
but the question of how best to provide rapid HIV testing, how to
perform urgent confirmatory testing in this setting, and how to best
present women with risk/benefit information and treatment options needs
systematic research. Integration of behavioral (i.e., to assess factors
related to lack of prenatal care, counseling and testing in the
delivery setting, informed consent issues, adherence to antiretroviral
therapy in the neonatal period, enhancement of social support
mechanisms) and biomedical sciences and a multi disciplinary research
team is strongly encouraged.
II. Follow-up of Perinatally HIV-Infected Children
Competing continuation applications are invited for the continued
prospective follow-up of HIV-infected children enrolled in the
Perinatal AIDS Collaborative Transmission Study (PACTS) between 1986
and 1998. Continued research areas of interest should include
identifying maternal and early infant markers of rapid versus chronic
pediatric disease progression, investigating host-related genetic
factors related to disease progression, and assessing adherence and
responses to the newest therapeutic interventions. As this unique and
well-characterized cohort of HIV-infected children ages into
adolescence, opportunities will arise for in-depth analysis of the
interrelationships among psycho social factors, pubertal development,
and disease progression, as well as for research into behavioral
interventions to prevent sexual HIV transmission.
This continuation project will support ongoing data collection and
analysis for the HIV-infected children and up to two comparison groups:
an HIV exposed but uninfected group (1:1 ratio matched for gender, site
and closest in birth date to infected child) originally followed in
PACTS, and a newly HIV-infected comparison group of children and
adolescents, to compare psycho social development of perinatally
infected children to these other groups. Follow-up should be done at
least every 6 months, and include at a minimum: (1) Information on HIV-
related clinical conditions, HIV-related medication use/adherence,
hospitalizations, and survival; (2) all data points available from
charts on viral load testing and lymphocyte immuno phenotyping as part
of treatment protocols or clinical care; (3) storage of blood specimens
for other HIV-related testing; (4) data on growth, pubertal
development, neurocognitive functioning, and quality of life; and (5)
data on school related outcomes such as grade failure, receipt of
specific special services, and any available results of school
achievement or developmental testing.
III. Parent Communication Training Interventions With Longitudinal
Follow-up Among Populations of Color at High Risk for Infection for
STD's Including HIV
HIV Prevention messages must reach individuals early in life when
healthy attitudes are still developing which most likely will lead to
lifelong behavioral practices. Parents are in a unique and powerful
position to shape young people's attitudes, values, and behaviors, and
to socialize them to become healthy adults. Recent research suggests
that giving parents information and communication skills about
sexuality and HIV risk can be an effective HIV/AIDS prevention
strategy. Applications are invited to conduct randomized intervention
trials of parent communication training interventions with longitudinal
follow-up among populations of color at high risk for infection for
STD's including HIV. The intent is to examine the impact of a parental
communication training program (i.e., minimal, basic, enhanced skills
training) on parents' communication with their children and
[[Page 27996]]
the subsequent attitudes, beliefs and behaviors about sex and drug use
of their children over time.
B. Eligible Applicants
Applications may be submitted by public and private nonprofit
organizations and by governments and their agencies; that is,
universities, colleges, research institutions, hospitals, other public
and private nonprofit organizations, State and local governments or
their bona fide agents, and federally recognized Indian tribal
governments, Indian tribes, or Indian tribal organizations.
For the MIRIAD study, only institutions serving disadvantaged
communities with high HIV seroprevalence among women of childbearing
age (i.e., approximately 1 percent prevalence or higher) and the
ability to recruit and retain a minimum of 20 HIV-infected pregnant
women per year not receiving prenatal care or with unknown HIV
serostatus before 36 weeks are invited to participate in this study.
Note: Public Law 104-65 states that an organization described in
section 501(c)(4) of the Internal Revenue Code of 1986 that engages
in lobbying activities is not eligible to receive Federal funds
constituting an award, grant, cooperative agreement, contract, loan,
or any other form.
C. Availability of Funds
I. Approximately $2.7 million is available in FY 1999 to fund
approximately 5 to 6 awards for mother infant rapid intervention at
delivery (MIRIAD). It is expected that the average award will be
$500,000, ranging from $300,000 to $700,000.
II. Approximately $800,000 is available in FY 1999 to fund
approximately 4 competitive continuation projects for follow-up of
Perinatally HIV-infected children and a comparison group. It is
expected that the average award will be $200,000, ranging from $150,000
to $250,000.
III. Approximately $900,000 is available in FY 1999 to fund
approximately 3 awards for intervention trials of parent communication
training. It is expected that the average award will be $300,000,
ranging from $200,000 to $400,000.
It is expected that all awards will begin on or about September 1,
1999, and will be made for a 12-month budget period within a project
period of up to 5 years. Funding estimates may change.
Continuation awards within an approved project period will be made
on the basis of satisfactory progress as evidenced by required reports
and the availability of funds.
Funding Preference
Preference will be given to achieve geographical diversity (e.g.,
Northeast, South, Central, and West).
For the Perinatally-HIV Infected Children Study, preference will be
given to competing continuation applications from satisfactorily
performing projects over applications for projects not already
receiving support for follow-up of perinatally-HIV infected children.
D. Program Requirements
In conducting activities to achieve the purpose of these programs,
the recipient will be responsible for the activities listed under
Recipient Activities and CDC will be responsible for conducting
activities listed under CDC Activities:
1. Recipient Activities
Recipients addressing the same research issue should be willing to
participate in collaborative studies with other CDC-sponsored
researchers, including using common data collection instruments,
specimen collection protocols, and data management procedures, as
determined in post-award grantee planning conferences. Recipients will
be required to pool data for analysis and publication. Recipients are
also required to work collaboratively as a study wide group to:
a. Develop the research study protocols and standardized data
collection forms across sites.
b. Identify, recruit, obtain informed consent from, and enroll an
adequate number of study participants as determined by the study
protocol and the program requirements.
c. Continue to follow study participants as determined by the study
protocol.
d. Establish procedures to maintain the rights and confidentiality
of all study participants.
e. Perform laboratory tests (when appropriate) and data analysis as
determined in the study protocol.
f. Collaborate and share data and specimens (when appropriate) with
other collaborators to answer specific research questions.
g. Contribute blood specimens (at least every 6-12 months depending
on the protocol requirements) for shipment and storage at a centralized
repository system at CDC.
h. Conduct data analysis with all collaborators as well as present
and publish research findings.
2. CDC Activities
a. Provide technical assistance in the design and facilitate in the
overall research project.
b. Facilitate and assist in the development of a research protocol
for IRB (institutional review board) review by all cooperating
institutions participating in the research project. The CDC IRB will
review and approve the protocol initially and on at least an annual
basis until the research project is completed.
c. Assist in designing a data management system.
d. Assist in performance of selected laboratory tests.
e. Work collaboratively with investigators to help coordinate
research activities across sites involved in the same research project.
f. Assist in the analysis of research information and the
presentation and publication of research findings.
E. Application Content
Use the information in the Program Requirements, Other
Requirements, and Evaluation Criteria sections to develop the
application content. Your application will be evaluated on the criteria
listed, so it is important to follow them in laying out your program
plan. Follow the directions for completing the application that are
found in the Public Health Service (PHS) 398 kit.
F. Submission and Deadline
Submit the original and five copies of PHS-398 (OMB Number 0925-
0001) (adhere to the instructions on the Errata Instruction Sheet for
PHS 398). Forms are in the application kit. On or before July 19, 1999,
submit the application to the Grants Management Specialist identified
in the ``Where to Obtain Additional Information'' section of this
announcement.
Deadline: Applications shall be considered as meeting the deadline
if they are either:
(a) Received on or before the deadline date; or
(b) Sent on or before the deadline date and received in time for
submission to the independent review group. (Applicants must request a
legibly dated U.S. Postal Service postmark or obtain a legibly dated
receipt from a commercial carrier or U.S. Postal Service. Private
metered postmarks shall not be acceptable as proof of timely mailing.)
Applications which do not meet the criteria in (a) and (b) above will
not be considered, and will be returned to the applicant.
G. Evaluation Criteria
Each application will be evaluated individually against the
following criteria by an independent review group appointed by CDC.
Applicants will be
[[Page 27997]]
ranked on a scale of 100 maximum points according to the research area
identified. All applicants must state which research category they are
addressing.
I. Mother Infant Rapid Intervention At Delivery (MIRIAD)
1. Recruitment, Retention and Adherence to Study Protocol (30
points).
a. Extent of applicant's experience in perinatal and pediatric HIV
infection epidemiologic research.
b. Evidence of ability to successfully recruit and follow HIV-
infected mothers and infants in longitudinal research studies.
c. Evidence of approximately 1% or greater HIV sero prevalence
among pregnant women in the catchment area described in the
application.
d. Ability to recruit and retain at least 20 and ideally over 30
HIV-infected pregnant women annually fulfilling the objectives of the
MIRIAD study. Linkages with other area hospitals and a Community
Advisory Board are strongly encouraged.
e. Ability to organize and provide a round-the-clock counseling and
voluntary rapid HIV testing program among women in labor presenting
with unknown HIV status; or immediately postpartum in first two days
following delivery.
f. Evidence of ability to collect complete data including
interviews of mothers in the immediate postpartum period and to obtain
a sufficiently large blood sample from HIV-infected mothers enrolled in
MIRIAD around the time of delivery.
g. Evidence of ability to collect complete data and to obtain
regular blood samples from HIV-exposed infants, with at least one blood
sample during the first 48 hours after birth.
h. Ability to oversee specimen collection for the timely
processing, storage, and retrieval of laboratory specimens as needed
for MIRIAD studies. This includes transfer of certain specimens to a
central repository at CDC and transfer of other specimens to designated
laboratories for specific laboratory studies.
i. Evidence of capability to address informed consent issues,
enhance social support and foster adherence to the antiretroviral
prophylaxis regimen, with special attention directed at adherence to
the neonatal component of the regimen.
2. Description and Justification of Research Plans (30 points).
a. Extent of familiarity and quality of experience pertinent to
proposed research activities.
b. Understanding of the research objectives as evidenced by the
high quality and scientific rigor of the proposed plan for research and
a study design that is appropriate to answer research questions.
c. The inclusion of innovative approaches to investigate the
feasibility of obtaining informed consent during labor for voluntary
rapid HIV testing, rapid implementation of antiretroviral therapy given
at labor and delivery or to the neonate, and adherence to neonatal
antiretroviral therapy.
d. Extent to which the applicant demonstrates willingness to work
with all successful applicants on development of a common core research
protocol across funded sites.
e. Feasibility of plans to follow study participants. This includes
demonstration of the experience of the investigator in following HIV-
infected mothers and infants, and the comprehensiveness of the plan to
protect the rights and confidentiality of all participants.
f. Thoroughness of plans for data management, data analysis, and
laboratory analysis; reasonableness of data collected; and statistical
rigor.
g. Extent to which proposal demonstrates feasible plans for
coordinating research activities of multiple local clinical sites,
where appropriate, and with CDC. Letters of support from cooperating
organizations that demonstrate the nature and extent of such
cooperation should be included.
h. The degree to which the applicant has met the CDC Policy
requirements regarding the inclusion of women, ethnic and racial groups
in the proposed research. This includes:
(i) The proposed plan for the inclusion of racial and ethnic
minority populations for appropriate representation;
(ii) The proposed justification when representation is limited or
absent;
(iii) A statement as to whether the design of the study is adequate
to measure differences when warranted;
(iv) A statement as to whether the plans for recruitment and
outreach for study participants include the process of establishing
partnerships with communities and recognition of mutual benefits.
3. Research and Intervention Capability (20 points).
a. Applicant's ability to carry out the proposed research as
demonstrated by the training and experience of the proposed research
team and organizational setting, including demonstration of ability to
collect, manage, and analyze accurate data in a timely manner.
b. Demonstration of working relationships with proposed
investigators and extent to which services to be provided by external
experts or consultants are documented by memoranda of agreement.
c. Demonstration of epidemiologic, behavioral, clinical,
administrative, laboratory, data management and statistical analysis
expertise needed to conduct proposed research.
4. Staffing, Facilities and Time line (20 points).
a. Availability of qualified and experienced personnel with
sufficient time dedicated to the proposed project.
b. Clarity of the described duties and responsibilities of project
personnel.
c. Adequacy of plans for project oversight to assure quality of
data.
d. Adequacy of facilities, equipment, data management resources,
and systems for ensuring data security and patient confidentiality.
e. Adequacy of time line for completion of project activities.
5. Other (not scored)
a. Budget: The extent to which it is reasonable, clearly justified,
consistent with the intended use of funds, and allowable. All budget
categories should be itemized.
b. Human Subjects: Does the application adequately address the
requirements of Title 45 CFR Part 46 for the protection of human
subjects? ____Yes ____No Comments:
II. Follow-up of Perinatally HIV-Infected Children
1. Retention and Adherence to Study Protocol (20 points).
a. Extent of applicant's experience in perinatal and pediatric HIV
infection epidemiologic research.
b. Evidence of ability to successfully follow HIV-infected children
in longitudinal research studies.
c. Evidence of ability to collect complete clinical, laboratory and
behavioral data and to obtain regular blood samples from HIV-infected
children; and demonstration of capability to re-enroll and follow a 1:1
ratio of HIV exposed but uninfected children from the PACTS cohort
originally followed at the site and/or a comparison group of newly HIV-
infected children and adolescents.
2. Description and Justification of Research Plans (30 points).
a. Extent of familiarity and quality of experience pertinent to
proposed research activities.
b. Understanding of the research objectives as evidenced by the
high quality of the proposed plan for research.
c. Originality of research, extent to which it does not replicate
past or
[[Page 27998]]
present research efforts, and direct relevance of research to guiding
current efforts to prevent HIV disease progression in children.
d. Feasibility of plans to follow study participants, and adequacy
of sample size to address research questions. This includes
demonstration of the experience of the investigator in following such
persons, and the comprehensiveness of the plan to protect the rights
and confidentiality of all participants.
e. Thoroughness of plans for data management, data analysis, and
laboratory analysis; reasonableness of data collected; and statistical
rigor.
f. Extent to which proposal demonstrates feasible plans for
coordinating research activities across multiple clinical sites, where
appropriate, and with CDC. Letters of support from cooperating
organizations that demonstrate the nature and extent of such
cooperation should be included.
g. The degree to which the applicant has met the CDC Policy
requirements regarding the inclusion of women, ethnic and racial groups
in the proposed research. This includes:
(i) The proposed plan for the inclusion of racial and ethnic
minority populations for appropriate representation;
(ii) The proposed justification when representation is limited or
absent;
(iii) A statement as to whether the design of the study is adequate
to measure differences when warranted;
(iv) A statement as to whether the plans for recruitment and
outreach for study participants include the process of establishing
partnerships with communities and recognition of mutual benefits.
3. Research Capability (30 points).
a. Applicant's ability to carry out the proposed research as
demonstrated by the training and experience of the proposed research
team, including demonstration of ability to collect, manage, and
analyze accurate data in a timely manner.
b. Demonstration of working relationships with proposed
investigators.
c. Demonstration of epidemiologic, behavioral, clinical,
administrative, laboratory, data management and statistical analysis
expertise needed to conduct proposed research.
4. Staffing, Facilities and Time Line (20 points).
a. Availability of qualified and experienced personnel, including
individuals with biomedical, behavioral, and epidemiological expertise.
b. Clarity of the described duties and responsibilities of project
personnel.
c. Adequacy of plans for project oversight to assure quality of
data.
d. Adequacy of facilities, equipment, data management resources,
and systems for ensuring data security and patient confidentiality.
e. Adequacy of time line for completion of project activities.
5. Other (not scored).
a. Budget: The extent to which it is reasonable, clearly justified,
consistent with the intended use of funds, and allowable. All budget
categories should be itemized.
b. Human Subjects: Does the application adequately address the
requirements of Title 45 CFR Part 46 for the protection of human
subjects? ____Yes ____No Comments:
III. Parent Communication Training Interventions With Longitudinal
Follow-up Among Populations of Color at High Risk for Infection for
STD's Including HIV
1. Description, Justification and Originality of Research Plans (25
points).
a. The inclusion of a detailed review of the scientific literature
and theoretical underpinnings on which the proposed research plan and
intervention are based. Application of science and theory to guide/
justify the generation and articulation of specific research questions
and hypotheses.
b. The originality of the proposed research and the extent to which
it builds on old science, extends or creates new science and does not
replicate past or present research efforts.
2. Familiarity with developmental and behavioral issues of children
and families. Access and ability to recruit, retain, and conduct
research with cohorts of 8 and 11 year old children and their families
(25 points).
a. The inclusion of abstracts, presentations, and manuscripts that
demonstrate the applicant's prior research expertise with children and
families, with particular regard to family communication, family based
interventions, and familial factors influencing risk taking behaviors.
b. Quality and description of methods used to identify, recruit ,
retain, and longitudinally follow cohorts of 8 and 11 year old children
and their families for 5 years, including the documented ability to
recruit and retain adequate numbers of study participants.
c. Quality, diversity, and description of methods used to collect
quantitative data during research, intervention, longitudinal tracking,
and evaluation phases of the research study with cohorts of 8 and 11
year old children and their families for 5 years.
d. The inclusion of abstracts, presentations, and manuscripts that
demonstrate the applicants ability to conduct longitudinal research
with children and families.
3. Intervention research plan (25 points).
a. Extent to which the proposed research design and methods are
appropriate for an intervention trial responsive to this request,
including randomization procedures, statistical power to detect
hypothesized differences, primary (attitudinal, cognitive, behavioral
and biological) and secondary (relevant mediating variables) outcome
measures, the reliability and validity of measures that will be used,
and procedures for maximizing external and internal validity (e.g.,
sampling strategies and retention procedures, respectively).
b. Appropriateness of description and justification of the proposed
research hypotheses, intervention plan, and intervention outcome
measures that will be addressed as part of the intervention trial.
c. Quality and scientific rigor of the research design, methods,
hypotheses, plan, and outcome measures that will be employed in the
intervention trial.
d. Extent to which the applicant demonstrates willingness to work
with CDC staff and consultants on development of a common research and
intervention protocol across sites.
e. Adequacy of procedures for obtaining informed consent and
maintaining participant confidentiality.
f. The degree to which the applicant has met the CDC Policy
requirements regarding the inclusion of women, ethnic and racial groups
in the proposed research. This includes:
(i) The proposed plan for the inclusion of racial and ethnic
minority populations for appropriate representation;
(ii) The proposed justification when representation is limited or
absent;
(iii) A statement as to whether the design of the study is adequate
to measure differences when warranted;
(iv) A statement as to whether the plans for recruitment and
outreach for study participants include the process of establishing
partnerships with communities and recognition of mutual benefits.
4. Research and intervention capability (15 points).
a. Applicant's ability to carry out the proposed research as
demonstrated by the training and experience of the proposed research
team and organizational setting, including
[[Page 27999]]
demonstration of previous behavioral/clinical interventions carried
out.
b. Ability of the applicant to conduct the proposed research as
reflected in the training, research, and behavioral intervention
experience of staff members.
c. Extent to which services to be provided by external experts,
consultants, or collaborating agencies are documented by memoranda of
agreement in the appendix.
5. Staffing, facilities, and time line (10 points).
a. Availability of qualified and experienced personnel with
sufficient time dedicated to the proposed project. Presence of
behavioral scientists in key leadership positions on the project.
b. Clarity of the described duties and responsibilities of project
personnel.
c. Adequacy of the facilities, equipment, data management
resources, and systems for ensuring data security.
d. Specificity and reasonableness of time line.
6. Other (not scored).
a. Budget: The extent to which it is reasonable, clearly justified,
consistent with the intended use of funds, and allowable. All budget
categories should be itemized.
b. Human Subjects: Does the application adequately address the
requirements of Title 45 CFR part 46 for the protection of human
subjects? ____Yes ____No Comments:
H. Other Requirements
Technical Reporting Requirements
Provide CDC with original plus two copies of
1. Annual progress report;
2. Financial status report, no more than 90 days after the end of
the budget period; and
3. Final financial status and performance reports, no more than 90
days after the end of the project period.
Send all reports to the Grants Management Specialist identified in
the ``Where to Obtain Additional Information'' section of this
announcement.
The following additional requirements are applicable to this
program. For a complete description of each, see the document entitled
``Descriptions of Other Requirements'' in the GMB homepage under
Program Announcements.
AR-1 Human Subjects Requirements.
AR-2 Requirements for Inclusion of Women and Racial and Ethnic
Minorities in Research.
AR-4 HIV/AIDS Confidentiality Provisions.
AR-5 HIV Program Review Panel Requirements.
AR-6 Patient Care
AR-7 Executive Order 12372 Review
AR-8 Public Health System Reporting Requirements
AR-9 Paperwork Reduction Act Requirements
R-10 Smoke-Free Workplace Requirements
AR-11 Healthy People 2000
AR-12 Lobbying Restrictions
I. Authority and Catalog of Federal Domestic Assistance Number
This program is authorized under sections 301(a) and 317 (k)(2)of
the Public Health Service Act, (42 U.S.C. 241(a) and 247(k) (2)), as
amended. The Catalog of Federal Domestic Assistance number is 93.943.
J. Where To Obtain Additional Information
To receive additional written information and to request an
application kit, call 1-888-GRANTS4 (1-888 472-6874). You will be asked
to leave your name and address and will be instructed to identify the
Announcement number of interest.
If you have questions after reviewing the contents of all the
documents, business management technical assistance may be obtained
from: Curtis Meusel, Grants Management Specialist, Grants Management
Branch, Procurement and Grants Office, Announcement 99102, Centers for
Disease Control and Prevention (CDC), Colgate Building Room 3000, 2920
Brandywine Road, M/S E-15, Atlanta, GA 30341, Telephone (770) 488-2738,
Email address ctm6@cdc.gov.
For program technical assistance, contact: Jeff Efird, MPA, Deputy
Chief, Epidemiology Branch, Division of HIV/AIDS Prevention
Surveillance & Epidemiology, National Center for HIV, STD, TB
Prevention, Centers for Disease Control and Prevention (CDC), 1600
Clifton Road, NE., Mailstop E-45 Atlanta, Georgia 30333, Telephone
(404) 639-6130, E-mail jle1@cdc.gov.
See also the CDC home page on the Internet to view and download all
CDC funding opportunities (i.e., program announcements) and applicable
application forms: HTTP://WWW.CDC.GOV.
Eligible applicants are encouraged to call before developing and
submitting their applications.
Dated: May 18, 1999.
John L. Williams,
Director, Procurement and Grants Office, Centers for Disease Control
and Prevention (CDC).
[FR Doc. 99-12996 Filed 5-21-99; 8:45 am]
BILLING CODE 4163-18-P
